Navigation Links
PARI Pharma's Altera Delivers Gilead's Cayston in Head-to-Head Study With Tobramycin Inhalation Solution
Date:6/21/2010

MONTEREY, Calif., June 21 /PRNewswire/ -- In a head-to-head, Phase III clinical trial of Cayston delivered by the Altera Nebulizer System versus tobramycin inhalation solution in cystic fibrosis patients with Pseudomonas aeruginosa, the co-primary endpoint of non-inferiority for mean percent change in forced expiratory volume in one second (FEV(1)) percent predicted after 28 days of treatment was achieved.  Patients receiving Cayston had a mean increase in FEV(1) percent predicted from baseline to day 28 of 8.35 percent compared to 0.55 percent for patients receiving tobramycin inhalation solution, meeting the statistical definition of superiority for the Cayston and Altera combination.  Safety results were similar across both arms of the study, with lower incidence of cough in patients receiving Cayston.  This data was presented by Gilead Sciences during a late-breaker oral session on Friday at the 33rd European Cystic Fibrosis Conference (ECFC).  

In the study, 268 patients were randomized to receive Cayston or tobramycin inhalation solution over a 24-week treatment period.  Approximately 85 percent of patients in the study had received at least three courses of inhaled tobramycin in the 12 months prior to randomization.  Final six-month study results will become available for presentation later this year.

"We are very pleased to see these encouraging results.  Our goal is to improve therapies for respiratory care using our advanced aerosol delivery platforms, such as eFlow Technology.  In addition to aerosol delivery expertise, PARI Pharma also contributed to the initial formulation of Cayston and optimized the formulation to the Altera Nebulizer System.  As evidenced in multiple clinical trials, Altera delivers Cayston in two to three minutes – a significant reduc
'/>"/>

SOURCE PARI Pharma
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. ePharmaSolutions Launches New Version of Electronic Monitor Visit Report Application With Industry-Leading Online and Offline Capabilities
2. Pharmasset to Present at the 28th Annual JPMorgan Healthcare Conference
3. Cytokine PharmaSciences Completes Phase I Study of Oral Anti-Inflammatory Agent, CPSI-2364
4. Pharmasset Reports Fiscal Year End 2009 Financial Results
5. Pharmasset Announces the Continued Enrollment of the Phase 2b Clinical Trial of RG7128 for the Treatment of Hepatitis C
6. Pharmasset to Present at Lazard Capital Markets Healthcare Conference
7. Sosei Assigns AD 923 Assets to Pharmasol
8. Pharmasset Reports Positive Preliminary Antiviral Data With PSI-7851 for the Treatment of Hepatitis C
9. Cytokine PharmaSciences Initiates Phase I Study of Oral Anti-Inflammatory Agent, CPSI-2364
10. Pharmasset to Present at Goldman Sachs and Needham Healthcare Conferences
11. ePharmaSolutions Clinical Trial Investigator Portal Wins Bio-IT World 2009 Best Practice Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... NEW YORK , Sept. 30, 2014 /PRNewswire/ ... - 2014 Summary Global Markets Direct,s, ... 2014, provides an overview of the Arbor Pharmaceuticals, ... report provides comprehensive information on the current therapeutic ... comparative analysis at various stages, therapeutics assessment by ...
(Date:9/30/2014)... According to the ... Product [Enzymes (Glycosyltransferase, Neuraminidase, Glycosidase), Instruments (HPLC, ... (Immunology, Oncology) & by End User - ... provides a detailed overview of the major ... and strategies impacting the global glycomics enzymes, ...
(Date:9/30/2014)... , Sept. 30, 2014 Valeant Pharmaceuticals International, ... today announced that the company,s Bridgewater, New ... the U.S. Food and Drug Administration (FDA) relating to ... with regards to Sculptra Aesthetic injectable, which was divested ... to the management of Valeant,s contract manufacturers (rather than ...
Breaking Medicine Technology:Arbor Pharmaceuticals, LLC. - Product Pipeline Review - 2014 2Arbor Pharmaceuticals, LLC. - Product Pipeline Review - 2014 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 2Glycobiology / Glycomics Market Worth $928.11 Million by 2019 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 4Valeant Pharmaceuticals' Bridgewater Location Receives Warning Letter From FDA 2
(Date:9/30/2014)... and radiotherapy at the same time could stop them ... published in Cancer Research * today (Wednesday). ... Manchester and funded by MedImmune, the global biologics research ... found that combining the two treatments helped the immune ... killed by the initial radiotherapy in mice with breast, ...
(Date:9/30/2014)... News) -- There,s no genetic evidence that high levels ... new study says. Some previous research had suggested ... against type 2 diabetes, raising the possibility of a ... disease. In this study, British researchers investigated the ... on genes that control blood levels of vitamin D. ...
(Date:9/30/2014)... Randy Dotinga HealthDay Reporter ... unemployment rates climb, women tend to put the brakes on ... out to be a permanent choice, new research suggests. ... not to have a child during tough economic times. But, ... women will remain childless into their 40s and beyond. ...
(Date:9/30/2014)... Health Day Reporter TUESDAY, Sept. ... are overweight or obese when diagnosed appear to face ... cancer, new research suggests. , , The finding didn,t ... the potential for developing other cancers associated with obesity. ... reported being overweight or obese prior to diagnosis had ...
(Date:9/30/2014)... [Brown University] Autism is no stranger to the ... African nation is access to clinical services, including reliable ... measure, for example, validated for use in Swahili, a ... study, however, researchers at Brown University and the University ... that they implemented at two sites in the country ...
Breaking Medicine News(10 mins):Health News:Immunotherapy could stop resistance to radiotherapy 2Health News:Gene Study Finds No Proof Vitamin D Guards Against Type 2 Diabetes 2Health News:Recessions May Thwart a Woman's Motherhood Plans Forever: Study 2Health News:Recessions May Thwart a Woman's Motherhood Plans Forever: Study 3Health News:Obesity Tied to Higher Cancer Risk for Colon Cancer Survivors 2Health News:Obesity Tied to Higher Cancer Risk for Colon Cancer Survivors 3Health News:New diagnostic approach for autism in Tanzania 2Health News:New diagnostic approach for autism in Tanzania 3Health News:New diagnostic approach for autism in Tanzania 4
... CHICAGO, Aug. 21 Illinois U.S. Senate candidate Cheryle Jackson ... achieve the dual goals of containing costs and expanding access to ... , Jackson said that health care cooperatives are not ... national public plan that competes with the private insurance industry because ...
... ... Attract, Retain and Serve Health Insurance Consumers , ... Orlando, FL (Vocus) August 21, 2009 -- As the ... is making individual consumers become more involved in the health insurance decision-making process, as ...
... Angeles, London, New Delhi, Singapore and Washington DC (August 21, ... could benefit from a lighter touch but from a ... created a touchy-feely robot that detects tougher tumour tissue in ... human. The technique also minimises tissue damage. Surgeons have ...
... Brown adipose tissue (BAT) brown fat, which is found ... lead to new ways of preventing obesity. Studies have ... obesity. Therefore, promoting BAT function could prevent or reduce obesity ... Symonds, Professor of Developmental Physiology in the School of Clincal ...
... Aug. 21 President Obama,s Council of Advisors on Science and ... reform, energy and the environment -- and the President is listening. ... little about our healthcare system that does not concern us," said ... A primary care physician, he noted that less than 20 ...
... and good rapport with physician is key, , FRIDAY, ... acid reflux is one of the most common complaints ... appear to work best to ease patients, suffering. , ... -- formally called gastroesophageal reflux disease (GERD) -- typically ...
Cached Medicine News:Health News:U.S. Senate Candidate Cheryle Jackson: 'Public Option Critical to Real Health Care Reform' 2Health News:Connextions Cited in Leading Industry Analyst Firm's 'Hype Cycle for Healthcare Payers' 2Health News:Connextions Cited in Leading Industry Analyst Firm's 'Hype Cycle for Healthcare Payers' 3Health News:Connextions Cited in Leading Industry Analyst Firm's 'Hype Cycle for Healthcare Payers' 4Health News:Robot's gentle touch aids delicate cancer surgery 2Health News:Robot's gentle touch aids delicate cancer surgery 3Health News:Daylight could help control our weight 2Health News:PCAST Members Advise President on Future of Healthcare, Energy 2Health News:Right Match of Drug, Doctor Can Boost Reflux Outcomes 2Health News:Right Match of Drug, Doctor Can Boost Reflux Outcomes 3
... Screen Tests are available in 14 configurations ... Designed using Microgenics Antibody Technology, the SureStep™ ... of care immunoassay targeted to detect MDMA ... and MDEA but no cross-reactivity to any ...
... The InstaCheck® multi-drug test device ... and easily. Negative results can ... as 3 minutes; positive results ... simple, one-time urine sample application ...
Accu-Stat Home Drug Test for Marijuana (THC), Cocaine (COC), Amphetamine (AMP), Methamphetamine (mAMP), Opiates (OPI), and Phencyclidine (PCP)....
... onsite test! QuickScreen™ multi-panel dip cards offer ... your choice of any conceivable combination of ... flexibility for your drug testing program. Just ... the built-in timer tells you when to ...
Medicine Products: